



## Protocol for the Examination of Biopsy Specimens From Patients With Gastrointestinal Stromal Tumor (GIST)

**Version:** 4.2.0.0

**Protocol Posting Date:** June 2021

The use of this protocol is recommended for clinical care purposes but is not required for accreditation purposes.

**This protocol may be used for the following procedures AND tumor types:**

Procedure	Description
Biopsy	
Tumor Type	Description
Gastrointestinal stromal tumor	

**The following should NOT be reported using this protocol:**

Procedure
Resection
Cytologic specimens

### Authors

Javier A. Laurini\*

With guidance from the CAP Cancer and CAP Pathology Electronic Reporting Committees.

\* Denotes primary author.

**Accreditation Requirements**

The use of this case summary is recommended for clinical care purposes but is not required for accreditation purposes. The core and conditional data elements are routinely reported. Non-core data elements are indicated with a plus sign (+) to allow for reporting information that may be of clinical value.

**Summary of Changes**

**v 4.2.0.0**

- General Reformatting

## Reporting Template

---

**Protocol Posting Date: June 2021**

**Select a single response unless otherwise indicated.**

### **CASE SUMMARY: (GASTROINTESTINAL STROMAL TUMOR (GIST): Biopsy)**

**Standard(s):** AJCC-UICC 8

*This case summary is recommended for reporting biopsy specimens, but is not required for accreditation purposes.*

### **CLINICAL**

#### **+Prebiopsy Treatment (select all that apply)**

- No known prebiopsy therapy
- Systemic therapy performed (specify type): \_\_\_\_\_
- Therapy performed, type not specified
- Not specified

### **SPECIMEN**

#### **Procedure**

- Core needle biopsy
- Endoscopic biopsy
- Other (specify): \_\_\_\_\_
- Not specified

### **TUMOR**

#### **Tumor Site (Note [A](#))**

- Esophagus: \_\_\_\_\_
  - Cervical esophagus
  - Thoracic esophagus
  - Abdominal esophagus
  - Upper third of esophagus
  - Middle third of esophagus
  - Lower third of esophagus
  - Esophagus, NOS
- Stomach: \_\_\_\_\_
  - Cardia of stomach
  - Fundus of stomach
  - Body of stomach
  - Gastric antrum
  - Pylorus
  - Lesser curvature of stomach, NOS
  - Greater curvature of stomach, NOS
  - Stomach, NOS
- Small Intestine: \_\_\_\_\_
  - Duodenum
  - Jejunum
  - Ileum (excluding ileocecal valve)
  - Meckel diverticulum (site of neoplasm)

- Small intestine, NOS
- Appendix: \_\_\_\_\_
- Colon: \_\_\_\_\_
- Cecum
- Ascending colon
- Hepatic flexure of colon
- Transverse colon
- Splenic flexure of colon
- Descending colon
- Sigmoid colon
- Colon, NOS
- Rectosigmoid junction: \_\_\_\_\_
- Rectum, NOS: \_\_\_\_\_
- Retroperitoneum: \_\_\_\_\_
- Peritoneum, including omentum and mesentery (specify parts): \_\_\_\_\_
- Peritoneum, NOS: \_\_\_\_\_
- Other (specify): \_\_\_\_\_
- Cannot be determined: \_\_\_\_\_
- Not specified

**Histologic Type**

- Gastrointestinal stromal tumor, spindle cell type
- Gastrointestinal stromal tumor, epithelioid type
- Gastrointestinal stromal tumor, mixed
- Gastrointestinal stromal tumor, other (specify): \_\_\_\_\_

**+Histologic Type Comment:** \_\_\_\_\_

**Mitotic Rate (Note B)**

*The required total count of mitoses is per 5 mm<sup>2</sup> on the glass slide section. With the use of older model microscopes, 50 HPF is equivalent to 5 mm<sup>2</sup>. Most modern microscopes with wider 40X lenses / fields require approximately 20 to 25 HPF to encompass 5 mm<sup>2</sup>. If necessary please measure field of view to accurately determine actual number of fields required to be counted on individual microscopes to encompass 5 mm<sup>2</sup>.*

- Specify mitotic rate per 5 mm<sup>2</sup>: \_\_\_\_\_ mitoses per 5 mm<sup>2</sup>
- Other (specify): \_\_\_\_\_
- Cannot be determined (explain): \_\_\_\_\_

**Histologic Grade (Note B)**

- G1, low grade (mitotic rate less than or equal to 5 per 5 mm<sup>2</sup>)
- G2, high grade (mitotic rate greater than 5 per 5 mm<sup>2</sup>)
- Other (specify): \_\_\_\_\_
- GX, cannot be assessed: \_\_\_\_\_

**+Necrosis**

- Not identified
- Present

**+Extent of Necrosis**

- Specify percentage: \_\_\_\_\_ %
- Other (specify): \_\_\_\_\_
- Cannot be determined: \_\_\_\_\_
- Cannot be determined: \_\_\_\_\_

**Treatment Effect (Note C)**

- No known prebiopsy therapy
- Not identified
- Present

**+Percentage of Viable Tumor**

- Specify percentage: \_\_\_\_\_ %
- Other (specify): \_\_\_\_\_
- Cannot be determined: \_\_\_\_\_
- Cannot be determined: \_\_\_\_\_

**Risk Assessment (Note D)**

- None
- Very low risk
- Low risk
- Moderate risk
- High risk
- Overtly metastatic
- Cannot be determined: \_\_\_\_\_

**+Tumor Comment:** \_\_\_\_\_

**ADDITIONAL FINDINGS**

**+Additional Findings (specify):** \_\_\_\_\_

**SPECIAL STUDIES (Note E)**

*The CAP GIST Biomarker Template can be used for reporting biomarkers. Pending biomarker studies should be listed in the Comments section of this report.*

**+Immunohistochemical Studies (select all that apply)**

- Not performed
- KIT (CD117)

**KIT (CD117)**

- Positive
- Negative
- Pending
- DOG1 (ANO1)

**DOG1 (ANO1)**

- Positive
- Negative
- Pending
- SDHB

**SDHB**

- Intact
- Deficient
- Pending
- SDHA

**SDHA**

- Intact
- Deficient

Pending  
 Other (specify): \_\_\_\_\_

**+Molecular Genetic Studies (e.g., KIT, PDGFRA, BRAF, SDHA/B/C/D, or NF1 mutational analysis)**

Submitted for analysis; results pending  
 Performed, see separate report: \_\_\_\_\_  
 Performed (specify method(s) and result(s)): \_\_\_\_\_  
 Not performed

**COMMENTS**

**Comment(s):** \_\_\_\_\_

## Explanatory Notes

---

### A. Location

Gastrointestinal stromal tumors may occur anywhere along the entire length of the tubal gut, as well as in extravisceral locations, which include the omentum, mesentery, pelvis, and retroperitoneum.<sup>1,2,3,4</sup> Typically, they arise from the wall of the gut and extend inward toward the mucosa, outward toward the serosa, or in both directions. Lesions that involve the wall of the gastrointestinal (GI) tract frequently cause ulceration of the overlying mucosa. Infrequently, lesions invade through the muscularis mucosae to involve the mucosae. Mucosal invasion is an adverse prognostic factor in numerous studies. Because the anatomic location along the GI tract affects prognosis, with location in the stomach having a more favorable prognosis, it is very important to specify anatomic location as precisely as possible.<sup>5</sup>

### References

1. Fletcher CD, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. *Hum Pathol*. 2002;33(5):459-465.
2. Miettinen M, Lasota J. Gastrointestinal stromal tumors: definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. *Virchows Arch*. 2001;438(1):1-12.
3. Reith JD, Goldblum JR, Lyles RH, Weiss SW. Extragastrointestinal (soft tissue) stromal tumors: an analysis of 48 cases with emphasis on histologic predictors of outcome. *Mod Pathol*. 2000;13(5):577-585.
4. WHO Classification of Tumours Editorial Board. Digestive system tumours. Lyon (France): International Agency for Research on Cancer; 2019. (WHO classification of tumours series, 5th ed; vol. 1).
5. Miettinen M, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. *Am J Surg Pathol*. 2005;29(1):52-68.

### B. Histologic Grade

Histologic grading, an important component of soft tissue sarcoma staging, is not well suited to GISTs, because most of these tumors have low or relatively low mitotic rates below the thresholds used for grading of soft tissue tumors, and because GISTs often manifest aggressive features with mitotic rates below the thresholds used for soft tissue tumor grading (the lowest tier of mitotic rates for soft tissue sarcomas being 10 mitoses per 10 HPF). In GIST staging, the grade is determined entirely by mitotic activity.<sup>1,2,3</sup>

GX: Grade cannot be assessed

G1: Low grade; mitotic rate  $\leq 5/5$  mm<sup>2</sup>

G2: High grade; mitotic rate  $>5/5$  mm<sup>2</sup>

The mitotic count should be initiated on an area that on screening magnification shows the highest level of mitotic activity and be performed as consecutive high-power fields (HPF). Stringent criteria should be applied when counting mitotic figures; pyknotic, dyskaryotic or apoptotic nuclei should not be regarded as mitosis.

Note: The required total count of mitoses is per 5 mm<sup>2</sup> on the glass slide section.<sup>2,3</sup> With the use of older model microscopes, 50 HPF is equivalent to 5 mm<sup>2</sup>. Most modern microscopes with wider 40X lenses/fields require approximately 20 to 25 HPF to encompass 5 mm<sup>2</sup>. If necessary, please measure

field of view to accurately determine actual number of fields required to be counted on individual microscopes to encompass 5 mm<sup>2</sup>.

**References**

1. Amin MB, Edge SB, Greene FL, et al, eds. AJCC Cancer Staging Manual. 8th ed. New York, NY: Springer; 2017.
2. Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol. 2006;23(2):70-83.
3. WHO Classification of Tumours Editorial Board. Digestive system tumours. Lyon (france): International Agency for Research on Cancer; 2019. (WHO classification of tumours series, 5th ed; vol. 1).

**C. Treatment Effect**

Gastrointestinal stromal tumors respond well to the newer targeted systemic therapies, imatinib mesylate and sunitib malate. The types of treatment effects that have been seen are hypocellularity, myxoid stroma, fibrosis, and necrosis. Nests of viable tumor cells are virtually always seen. Because all of these histologic features can be seen in untreated GISTs, it is not possible to know whether they are due to treatment or not. As a practical compromise, we think it is best to report the percentage of viable tumor after treatment.

**D. Risk Assessment**

Because GISTs can recur many years after initial excision, we now regard most GISTs as having at least some potential for distant metastasis. This concept was originally the result of a National Cancer Institute-sponsored consensus conference that was held in 2002.<sup>1</sup> More specific data generated by large follow-up studies refined the biologic potential assessment.<sup>2,3,4,5,6</sup> Criteria obtained from those data were adopted in a National Cancer Care Network (NCCN) Task Force report on GIST.<sup>7</sup> We have adopted the criteria for risk stratification, as indicated in Table 1.<sup>2,3,4,5,6</sup> The scheme includes anatomic site as a factor, because small bowel GISTs carry a higher risk of progression than gastric GISTs of similar size and mitotic activity. This prognostic assessment applies best to KIT/PDGFRα mutant GISTs whereas SDD-deficient GISTs are more unpredictable.<sup>8</sup> For anatomic sites not listed in this table, such as esophagus, mesentery, and peritoneum, or in the case of “insufficient data,” it is best to use risk criteria for jejunum/ileum.

**Table 1. Guidelines for Risk Assessment of Primary Gastrointestinal Stromal Tumor (GIST)**

Tumor Parameters		Risk of Progressive Disease#(%)			
Mitotic Rate	Size	Gastric	Duodenum	Jejunum/Ileum	Rectum
<b>≤5 per 5 mm</b>	≤2 cm	None (0%)	None (0%)	None (0%)	None (0%)
	>2 - ≤5 cm	Very low (1.9%)	Low (8.3%)	Low (4.3%)	Low (8.5%)
	>5 - ≤10 cm	Low (3.6%)	(Insufficient data)	Moderate (24%)	(Insufficient data)
	>10 cm	Moderate (10%)	High (34%)	High (52%)	High (57%)
<b>&gt;5 per 5 mm</b>	≤2 cm	None	(Insufficient data)	High	High (54%)
	>2 - ≤5 cm	Moderate (16%)	High (50%)	High (73%)	High (52%)
	>5 - ≤10 cm	High (55%)	(Insufficient data)	High (85%)	(Insufficient data)
	>10 cm	High (86%)	High (86%)	High (90%)	High (71%)



Adapted with permission from Miettinen and Lasota.<sup>6</sup> Copyright 2006 by Elsevier.

# Defined as metastasis or tumor-related death.

## Denotes small number of cases.

Data based on long-term follow-up of 1055 gastric, 629 small intestinal, 144 duodenal, and 111 rectal GISTs from the pre-imatinib era.<sup>2,3,4,6</sup>

Note: See Note B, "Histologic Grade," regarding the number of high power fields to evaluate.

## References


1. Fletcher CD, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. *Hum Pathol*. 2002;33(5):459-465.
2. Miettinen M, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. *Am J Surg Pathol*. 2005;29(1):52-68.
3. Miettinen M, Furlong M, Sarlomo-Rikala M, Burke A, Sobin LH, Lasota J. Gastrointestinal stromal tumors, intramural leiomyomas, and leiomyosarcomas in the rectum and anus: a clinicopathologic, immunohistochemical, and molecular genetic study of 144 cases. *Am J Surg Pathol*. 2001;25(9):1121-1133.
4. Miettinen M, Kopczynski J, Makhlof HR, et al. Gastrointestinal stromal tumors, intramural leiomyomas, and leiomyosarcomas in the duodenum: a clinicopathologic, immunohistochemical, and molecular genetic study of 167 cases. *Am J Surg Pathol*. 2003;27(5):625-641.
5. Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. *Semin Diagn Pathol*. 2006;23(2):70-83.
6. Miettinen M, Makhlof H, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the jejunum and ileum: a clinicopathologic, immunohistochemical, and molecular genetic study of 906 cases before imatinib with long-term follow-up. *Am J Surg Pathol*. 2006;30(4):477-489.
7. Demetri GD, Benjamin RS, Blanke CD, et al; NCCN Task Force. NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines. *J Natl Compr Canc Netw*. 2007;5(Suppl 2):S1-S29.
8. WHO Classification of Tumours Editorial Board. Digestive system tumours. Lyon (France): International Agency for Research on Cancer; 2019. (WHO classification of tumours series, 5th ed; vol. 1).

## E. Ancillary Studies

### Immunohistochemistry

Because of the advent of small-molecule kinase inhibitor therapy in the treatment of GIST (see the following), it has become imperative to distinguish GIST from its histologic mimics, mainly leiomyoma, leiomyosarcoma, schwannoma, and desmoid fibromatosis.<sup>12</sup> Immunohistochemistry is instrumental in the workup of GIST. For the initial work up of GIST, a basic immunohistochemical panel including CD117 (KIT), DOG1 (Ano1), Desmin, S100 protein and CD34 is recommended. GISTs are immunoreactive for KIT (CD117) (approximately 95%) and/or DOG1(>99%).<sup>3,4,5</sup> KIT immunoreactivity is usually strong and diffuse but can be more focal in unusual cases (Figure 1, A and B). It is not unusual for GISTs to exhibit dot-like perinuclear staining (Figure 1, C), while less commonly, some cases exhibit membranous staining (Figure 1, D). These patterns do not clearly correlate with mutation type or response to therapy. Most KIT-negative / DOG1 positive GISTs are gastric or extra-visceral GISTs and almost invariably harbor a *platelet-derived growth factor receptor A (PDGFRA)* mutation.<sup>6</sup> DOG1 expression is not related to mutational status in GISTs, and it may be a useful marker to identify a subset of patients with CD117-negative GISTs, who might benefit from targeted therapy.<sup>4,5</sup> Approximately 70% of GISTs are positive for CD34, 30% to 40% are positive for smooth muscle actin, 5% are positive for S100 protein (usually focal), 5% are positive for desmin (usually focal), and 1% to 2% are positive for keratin (weak/focal).<sup>7</sup>

Since succinate dehydrogenase (SDH)-deficient GISTs have specific implications (see the following), it is recommended to screen all gastric GISTs for loss of SDH by immunohistochemistry, usually best accomplished by staining for SDHB, which is lost in all subtypes of SDH-deficient GISTs.<sup>8,9,10,11</sup> Mutations in SDHA are detected in 30% of SDH-deficient GISTs and loss of expression of SDHA specifically identifies tumors with SDHA mutations; other SDH-deficient GISTs show normal (intact) cytoplasmic staining for SDHA.<sup>12,13</sup> Patients with SDH-deficient GIST should be referred to a genetic counselor for appropriate work up.



**Figure 1.** Patterns of KIT staining in gastrointestinal stromal tumor (GIST). A. Diffuse and strong immunoreactivity in a typical GIST. B. Focal and weak pattern in an epithelioid gastric GIST with a *PDGFRA* mutation. C. Dot-like perinuclear staining. D. Membranous pattern. (Original magnification X400.)


### Molecular Analysis

Approximately 75% of GISTs possess activating mutations in the *KIT* gene, whereas another 10% have activating mutations in the *PDGFRA* gene.<sup>14,15,16,17</sup> These mutations result in virtually full-length KIT proteins that exhibit ligand-independent activation. *KIT* and *PDGFRA* each contain 21 exons. However, mutations cluster within “hotspots”: exons 9, 11, 13, and 17 in *KIT*, and exons 12, 14, and 18 in *PDGFRA* (Figure 2). About 5% to 10% of GISTs appear to be negative for both *KIT* and *PDGFRA* mutations. The most recent NCCN Task Force on GIST strongly encourages that *KIT* and *PDGFRA* mutational analysis be performed if tyrosine kinase inhibitors (TKIs) are considered as part of the treatment plan for unresectable or metastatic disease and that mutational analysis be considered for patients with primary disease, particularly those with high-risk tumors. *KIT* and *PDGFRA* mutation status can be determined easily from paraffin-embedded tissue. Secondary or acquired mutations can be associated with development of tumor resistance in the setting of long-term imatinib mesylate treatment. These are usually point mutations that occur most commonly in *KIT* exons 13, 14, and 17.<sup>18</sup> The clinical utility of these mutations is an evolving concept, but it is important not to confuse them with the primary or initial mutation in GIST.

Recent studies focusing on the molecular classification of GISTs recognized two major subgroups : succinate dehydrogenase (SHD)-competent and SDH-deficient GISTs, both of which can arise in the sporadic or familial setting.<sup>8,9</sup> SDH-competent GISTs include tumors with mutations of *KIT* and *PDGFRA*

as well of a subset of wild-type GISTs with mutations mainly in *NF1* and *BRAF* genes. On the other hand, *SDH*-deficient GISTs include tumors with a genetic alteration in any of the *SDH* subunits leading to *SDH* dysfunction.

*SDH*-deficient GISTs represent approximately 8% of GISTs and comprise some sporadic cases, the majority of pediatric GISTs, and two forms of syndromic GISTs (Carney triad and Carney-Stratakis syndrome). *SDH* is a mitochondrial enzyme comprising four subunits (*SDHA*, *SDHB*, *SDHC* and *SDHD*) that is involved in the Krebs cycle. Genetic alteration of any of the four subunits results in *SDH* dysfunction and subsequent loss of *SDHB* expression by immunohistochemistry. *SDH* deficient GISTs arise almost exclusive in the stomach, affect predominantly female patients and tend to manifest at a young age. Pathologic features associated with *SDH*-deficient tumors include multinodular and/or plexiform growth pattern, epithelioid morphology, lymphovascular invasion, nodal involvement and frequent metastasis to the liver and peritoneum. Importantly, germline mutations in the genes coding for any of the *SDH* subunits can lead to paragangliomas/pheochromocytomas, *SDH*-deficient renal cell carcinoma and pituitary tumors in addition to GISTs. Since *SDH*-deficient GISTs typically require germline genetic testing possibly including family members as well as possible surveillance for paragangliomas/pheochromocytomas, it is recommended that all gastric GISTs be screened for loss of *SDHB* by immunohistochemistry. All patients with *SDH*-deficient GISTs identified by loss of *SDHB* stain should be referred to a genetic counselor.



**Figure 2.** Locations and frequency of activating *KIT* and *PDGFRA* mutations in GIST. Adapted with permission from Heinrich et al.<sup>14</sup> Copyright 2003 by the American Society of Clinical Oncology. All rights reserved.

*KIT* and *PDGFRA* are excellent targets for small-molecule tyrosine kinase inhibitors, and two compounds of this class, imatinib mesylate (Gleevec, Novartis Pharmaceuticals, Basel, Switzerland) and sunitinib malate (Sutent, Pfizer Pharmaceuticals, New York, New York), have shown efficacy in clinical trials and have been approved by the US Food and Drug Administration for the treatment of GIST.<sup>19,20,21</sup> *SDH*-deficient GISTs are usually resistant to imatinib but may have a higher probability of response to sunitinib.<sup>8</sup> Because different tyrosine kinase inhibitors (TKIs) may have more efficacy in genetic subsets of GIST, oncologists may want to know the mutation status of each GIST, because this may impact which drug each patient should receive.<sup>14,22</sup> Secondary resistance mutations may also affect drug selection as their significance is further defined.

## References

1. Hornick JL, Fletcher CD. Immunohistochemical staining for KIT (CD117) in soft tissue sarcomas is very limited in distribution. *Am J Clin Pathol*. 2002;117(2):188-193.
2. Miettinen M, Sobin LH, Sarlomo-Rikala M. Immunohistochemical spectrum of GISTs at different sites and their differential diagnosis with a reference to CD117 (KIT). *Mod Pathol*. 2000;13(10):1134-1142.
3. Sarlomo-Rikala M, Kovatich AJ, Barusevicius A, Miettinen M. CD117: a sensitive marker for gastrointestinal stromal tumors that is more specific than CD34. *Mod Pathol*. 1998;11(8):728-734.
4. Espinosa I, Lee CH, Kim MK, et al. A novel monoclonal antibody against DOG1 is a sensitive and specific marker for gastrointestinal stromal tumors. *Am J Surg Pathol*. 2008;32(2):210–218.
5. Miettinen M, Wang ZF, Lasota J. DOG1 antibody in the differential diagnosis of gastrointestinal stromal tumors: a study of 1840 cases. *Am J Surg Pathol*. 2009;33:1401–1408.
6. Medeiros F, Corless CL, Duensing A, et al. KIT-negative gastrointestinal stromal tumors: proof of concept and therapeutic implications. *Am J Surg Pathol*. 2004;28(7):889-894.
7. Fletcher CD, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. *Hum Pathol*. 2002;33(5):459-465.
8. Mei L, Smith SC, Faber AC, et al. Gastrointestinal Stromal Tumors: The GIST of Precision Medicine. *Trends Cancer*. 2018;4:74-91.
9. Gill AJ. Succinate dehydrogenase (SDH) and mitochondrial driven neoplasia. *Pathology*. 2012 Jun;44(4):285-92.
10. Gill AJ, Benn DE, Chou A, et al. Immunohistochemistry for SDHB triages genetic testing of SDHB, SDHC, and SDHD in paraganglioma-pheochromocytoma syndromes. *Hum Pathol*. 2010 Jun;41(6):805-14.
11. Doyle LA, Nelson D, Heinrich MC, et al. Loss of succinate dehydrogenase subunit B (SDHB) expression is limited to a distinctive subset of gastric wild-type gastrointestinal stromal tumours: a comprehensive genotype-phenotype correlation study. *Histopathology*. 2012;61(5):801-809.
12. Wagner AJ, Remillard SP, Zhang YX, et al. Loss of expression of SDHA predicts SDHA mutations in gastrointestinal stromal tumors. *Mod Pathol*. 2013;26(2):289-294.
13. Dwight T, Benn DE, Clarkson A, et al. Loss of SDHA expression identifies SDHA mutations in succinate dehydrogenase-deficient gastrointestinal stromal tumors. *Am J Surg Pathol*. 2013;37(2):226-233.
14. Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. *J Clin Oncol*. 2003;21(23):4342-4349.
15. Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. *Science*. 2003;299(5607):708-710.
16. Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. *Science*. 1998;279(5350):577-580.
17. Rubin BP, Singer S, Tsao C, et al. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. *Cancer Res*. 2001;61(22):8118-8121.
18. Heinrich MC, Corless CL, Blanke CD, et al. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. *J Clin Oncol*. 2006;24(29):4764-4774.
19. Demetri GD, Benjamin RS, Blanke CD, et al; NCCN Task Force. NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines. *J Natl Compr Canc Netw*. 2007;5(Suppl 2):S1-S29.
20. Demetri GD. Targeting the molecular pathophysiology of gastrointestinal stromal tumors with imatinib: mechanisms, successes, and challenges to rational drug development. *Hematol Oncol Clin North Am*. 2002;16(5):1115-1124.
21. Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. *Lancet*. 2006;368(9544):1329-1338.
22. Corless CL, Schroeder A, Griffith D, et al. PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. *J Clin Oncol*. 2005;23(23):5357-5364.